Evidence map›Paper›PMID 31919691›Full record

ArticleInternational journal of clinical oncology2020

Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.

Shintaro Narita, Shingo Hatakeyama, Masahiro Takahashi, Toshihiko Sakurai, Sadafumi Kawamura, Senji Hoshi, Masanori Ishida, Toshiaki Kawaguchi, Shigeto Ishidoya, Jiro Shimoda and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Article
  3. Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shintaro NaritaDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. naritashintaro@gmail.com.ORCID http://orcid.org/0000-0003-2988-1860
Shingo HatakeyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Masahiro TakahashiDepartment of Urology, Tohoku University School of Medicine, Sendai, Japan.
Toshihiko SakuraiDepartment of Urology, Yamagata University School of Medicine, Yamagata, Japan.
Sadafumi KawamuraDepartment of Urology, Miyagi Cancer Center, Natori, Japan.
Senji HoshiDepartment of Urology, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Masanori IshidaDepartment of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan.
Toshiaki KawaguchiDepartment of Urology, Aomori Prefectural Central Hospital, Aomori, Japan.
Shigeto IshidoyaDepartment of Urology, Sendai City Hospital, Sendai, Japan.
Jiro ShimodaDepartment of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan.
Hiromi SatoDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Atsushi KoizumiDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Koji MitsuzukaDepartment of Urology, Tohoku University School of Medicine, Sendai, Japan.
Tatsuo TochigiDepartment of Urology, Miyagi Cancer Center, Natori, Japan.
Norihiko TsuchiyaDepartment of Urology, Yamagata University School of Medicine, Yamagata, Japan.
Chikara OhyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Yoichi AraiDepartment of Urology, Tohoku University School of Medicine, Sendai, Japan.
Kyoko NomuraDepartment of Public Health, Akita University School of Medicine, Akita, Japan.
Tomonori HabuchiDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClinical outcomes of patients with newly diagnosed metastatic hormone-naïve prostate cancer (mHNPC) and initially treated with androgen deprivation therapy (ADT) were evaluated.

methodsThe medical records of 605 consecutive mHNPC patients with initial ADT or combined androgen blockade (CAB) at nine study centers between 2008 and 2016 were retrospectively reviewed. Castration-resistant prostate cancer (CRPC)-free and overall survival (OS) were estimated by the Kaplan-Meier method. The association of pretreatment risk factors with CRPC-free survival and OS was evaluated by Cox proportional hazard models and differences in survival were classified by the number of risk factors.

resultsMedian follow-up was 2.95 years, median CRPC-free survival was 21.9 months and median OS was 5.37 years. Multivariable analysis found that four risk factors, a Gleason score ≥ 9, lymph node metastasis, an extent of disease score ≥ 2, and serum LDH of > 220 IU were independently associated with both CRPC-free survival and OS. Median CRPC-free survival of low-risk patients with no or one factor was 86.5 months, 17.9 months in intermediate-risk patients with two or three factors, and 11.0 months in high-risk patients with four factors. Median OS was 4.72 years in intermediate- and 2.44 years in high-risk patients. It was not reached in low-risk patients.

conclusionIn this series, CRPC-free and OS of a subset of mHNPC patients in Japan who were treated with ADT or CAB had better CRPC-free and overall survivals in Japan. Risk-adapted treatment based on the presence of novel prognostic factors may be beneficial for selected mHNPC patients.

Indexed as

AgedAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsAsian PeopleHumansLymphatic MetastasisMalePrognosisProportional Hazards ModelsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantRetrospective StudiesAndrogen AntagonistsAndrogen deprivation therapyCastration-resistant prostate cancer-free survivalHormone-naïveHormone-sensitiveMetastaticOverall survivalProstate caner

Identifiers

PMID31919691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.